AstraZeneca plc (LON:AZN) was upgraded by research analysts at Investec from a “hold” rating to a “buy” rating in a report released on Wednesday, August 9th, Marketbeat reports. The brokerage presently has a GBX 4,900 ($63.61) price objective on the biopharmaceutical company’s stock, down from their prior price objective of GBX 5,000 ($64.91). Investec’s price target would suggest a potential upside of 10.19% from the stock’s previous close.
Several other analysts have also recently commented on the company. Citigroup Inc. reiterated a “buy” rating and issued a GBX 6,000 ($77.89) target price on shares of AstraZeneca plc in a report on Thursday, July 13th. Deutsche Bank AG reduced their target price on AstraZeneca plc from GBX 5,500 ($71.40) to GBX 5,350 ($69.45) and set a “buy” rating on the stock in a report on Friday, April 28th. Barclays PLC reiterated an “overweight” rating and issued a GBX 6,000 ($77.89) target price on shares of AstraZeneca plc in a report on Friday, April 28th. Jefferies Group LLC reduced their target price on AstraZeneca plc from GBX 5,500 ($71.40) to GBX 5,300 ($68.80) and set a “hold” rating on the stock in a report on Wednesday, July 12th. Finally, HSBC Holdings plc lowered AstraZeneca plc to a “reduce” rating and set a GBX 4,500 ($58.42) price target on the stock. in a research note on Tuesday, July 4th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the stock. AstraZeneca plc presently has an average rating of “Hold” and a consensus price target of GBX 4,932.67 ($64.04).
AstraZeneca plc (LON:AZN) opened at 4447.00 on Wednesday. The stock has a 50 day moving average of GBX 4,818.59 and a 200 day moving average of GBX 4,862.48. AstraZeneca plc has a 52 week low of GBX 3,996.00 and a 52 week high of GBX 5,520.00. The company’s market cap is GBX 56.30 billion.
TRADEMARK VIOLATION WARNING: This story was originally posted by BNB Daily and is the sole property of of BNB Daily. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.baseball-news-blog.com/2017/08/19/astrazeneca-plc-lonazn-lifted-to-buy-at-investec-updated.html.
In other AstraZeneca plc news, insider Nazneen Rahman acquired 39 shares of AstraZeneca plc stock in a transaction on Thursday, July 27th. The stock was purchased at an average price of GBX 4,370 ($56.73) per share, for a total transaction of £1,704.30 ($2,212.51).
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.